Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Gemcitabine by Johnson & Johnson for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer): Likelihood of Approval
Gemcitabine is under clinical development by Johnson & Johnson and currently in Phase III for Non Muscle Invasive Bladder Cancer...
Gemcitabine by Johnson & Johnson for Transitional Cell Carcinoma (Urothelial Cell Carcinoma): Likelihood of Approval
Gemcitabine is under clinical development by Johnson & Johnson and currently in Phase II for Transitional Cell Carcinoma (Urothelial Cell...
Risk adjusted net present value: What is the current valuation of Johnson & Johnson's Gemcitabine?
Gemcitabine is a small molecule commercialized by Johnson & Johnson, with a leading Phase III program in Non Muscle Invasive...
Risk adjusted net present value: What is the current valuation of Johnson & Johnson's Gemcitabine?
Gemcitabine is a small molecule commercialized by Johnson & Johnson, with a leading Phase III program in Non Muscle Invasive...